SlideShare uma empresa Scribd logo
1 de 2
Baixar para ler offline
7/20/2014 WHO MEC for patients with endocrine disorders
http://www.uptodate.com.myaccess.library.utoronto.ca/contents/image?imageKey=OBGYN%2F69329&rank=1~150&search=contracep%C3%A7%C3%A3o&source=image_view&view=print&topicKey=OBGYN/5459&source=se… 1/2
Official reprint from UpToDate® 
www.uptodate.com ©2014 UpToDate®
World Health Organization medical eligibility for contraceptive use: Endocrine conditions
Condition COC CIC P/R POP
DMPA
NET­EN
LNG/ETG
Implants
Cu­IUD LNG­IUD
Diabetes
History of gestational disease 1 1 1 1 1 1 1 1
Non­vascular disease
Non­insulin dependent 2 2 2 2 2 2 1 2
Insulin dependent 2 2 2 2 2 2 1 2
Nephropathy/retinopathy/neuropathy 3/4 3/4 3/4 2 3 2 1 2
Other vascular disease or diabetes of >20 years' duration 3/4 3/4 3/4 2 3 2 1 2
Thyroid disorders
Simple goitre 1 1 1 1 1 1 1 1
Hyperthyroid 1 1 1 1 1 1 1 1
Hypothyroid 1 1 1 1 1 1 1 1
1: A condition for which there is no restriction for the use of the contraceptive method.
2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.
3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method.
4: A condition which represents an unacceptable health risk if the contraceptive method is used.
COC: low­dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen­only pill;
DMPA: depot medroxyprogesterone acetate; NET­EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill;
Cu­IUD: copper intrauterine device; LNG­IUD: levonorgestrel­releasing IUDs; E­IUD: copper­IUD for emergency contraception; BARR: barrier methods; FAB:
fertility awareness­based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization.
Reproduced with permission from: http://www.who.int/reproductive­health/publications/mec/summary.html. Copyright © 2006 World Health Organization.
7/20/2014 WHO MEC for patients with endocrine disorders
http://www.uptodate.com.myaccess.library.utoronto.ca/contents/image?imageKey=OBGYN%2F69329&rank=1~150&search=contracep%C3%A7%C3%A3o&source=image_view&view=print&topicKey=OBGYN/5459&source=se… 2/2
Graphic 69329 Version 2.0

Mais conteúdo relacionado

Semelhante a Who mec for patients with endocrine disorders

Kidney Diseases Prediction Using Hybrid Ensemble Learning
Kidney Diseases Prediction Using Hybrid Ensemble LearningKidney Diseases Prediction Using Hybrid Ensemble Learning
Kidney Diseases Prediction Using Hybrid Ensemble LearningIRJET Journal
 
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...QUESTJOURNAL
 
Ocular Manifestation of Diabetes Mellitus
Ocular Manifestation of Diabetes MellitusOcular Manifestation of Diabetes Mellitus
Ocular Manifestation of Diabetes MellitusJoobin Khadamy . MD
 
Post pn-445
Post pn-445Post pn-445
Post pn-445t7260678
 
Post pn-445 (1)
Post pn-445 (1)Post pn-445 (1)
Post pn-445 (1)t7260678
 
Post pn-445 (2)
Post pn-445 (2)Post pn-445 (2)
Post pn-445 (2)t7260678
 
DM & CVD, the double trouble.pptx
DM & CVD, the double trouble.pptxDM & CVD, the double trouble.pptx
DM & CVD, the double trouble.pptxAhmedMagdy547986
 
GLUCAGON: AI-Based Insulin Dosage Prediction Application
GLUCAGON: AI-Based Insulin Dosage Prediction ApplicationGLUCAGON: AI-Based Insulin Dosage Prediction Application
GLUCAGON: AI-Based Insulin Dosage Prediction ApplicationIRJET Journal
 
Ueda2015 type 2 dm burden consequences_dr.mohamed mashahit
Ueda2015 type 2 dm burden   consequences_dr.mohamed mashahitUeda2015 type 2 dm burden   consequences_dr.mohamed mashahit
Ueda2015 type 2 dm burden consequences_dr.mohamed mashahitueda2015
 
CCO_CLD_in_T2D_Downloadable_1.pptx
CCO_CLD_in_T2D_Downloadable_1.pptxCCO_CLD_in_T2D_Downloadable_1.pptx
CCO_CLD_in_T2D_Downloadable_1.pptxAnshitaAggarwal7
 
Diabetic retinopathy for GENERAL OPHTHALMOLOGIST
Diabetic retinopathy for GENERAL OPHTHALMOLOGISTDiabetic retinopathy for GENERAL OPHTHALMOLOGIST
Diabetic retinopathy for GENERAL OPHTHALMOLOGISTAjayDudani1
 
Avengers of DME -AJAY DUDANI MUMBAI RETINA CENTRE
Avengers of DME -AJAY DUDANI MUMBAI RETINA CENTREAvengers of DME -AJAY DUDANI MUMBAI RETINA CENTRE
Avengers of DME -AJAY DUDANI MUMBAI RETINA CENTREAjayDudani1
 
PSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptx
PSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptxPSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptx
PSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptxRhoda Isip
 

Semelhante a Who mec for patients with endocrine disorders (20)

Kidney Diseases Prediction Using Hybrid Ensemble Learning
Kidney Diseases Prediction Using Hybrid Ensemble LearningKidney Diseases Prediction Using Hybrid Ensemble Learning
Kidney Diseases Prediction Using Hybrid Ensemble Learning
 
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
Incidence of Glaucoma & Diabetic Retinopathy in Patients with Diabetes Mellit...
 
Ocular Manifestation of Diabetes Mellitus
Ocular Manifestation of Diabetes MellitusOcular Manifestation of Diabetes Mellitus
Ocular Manifestation of Diabetes Mellitus
 
Post pn-445
Post pn-445Post pn-445
Post pn-445
 
Post pn-445
Post pn-445Post pn-445
Post pn-445
 
Post pn-445 (1)
Post pn-445 (1)Post pn-445 (1)
Post pn-445 (1)
 
Post pn-445 (2)
Post pn-445 (2)Post pn-445 (2)
Post pn-445 (2)
 
Post pn-445
Post pn-445Post pn-445
Post pn-445
 
DM & CVD, the double trouble.pptx
DM & CVD, the double trouble.pptxDM & CVD, the double trouble.pptx
DM & CVD, the double trouble.pptx
 
GLUCAGON: AI-Based Insulin Dosage Prediction Application
GLUCAGON: AI-Based Insulin Dosage Prediction ApplicationGLUCAGON: AI-Based Insulin Dosage Prediction Application
GLUCAGON: AI-Based Insulin Dosage Prediction Application
 
Ueda2015 type 2 dm burden consequences_dr.mohamed mashahit
Ueda2015 type 2 dm burden   consequences_dr.mohamed mashahitUeda2015 type 2 dm burden   consequences_dr.mohamed mashahit
Ueda2015 type 2 dm burden consequences_dr.mohamed mashahit
 
Prevention of Diabetes visual impairment and blindness
Prevention of  Diabetes visual impairment and blindness Prevention of  Diabetes visual impairment and blindness
Prevention of Diabetes visual impairment and blindness
 
MedVET module 3 EN
MedVET module 3 ENMedVET module 3 EN
MedVET module 3 EN
 
CCO_CLD_in_T2D_Downloadable_1.pptx
CCO_CLD_in_T2D_Downloadable_1.pptxCCO_CLD_in_T2D_Downloadable_1.pptx
CCO_CLD_in_T2D_Downloadable_1.pptx
 
Diabetic retinopathy for GENERAL OPHTHALMOLOGIST
Diabetic retinopathy for GENERAL OPHTHALMOLOGISTDiabetic retinopathy for GENERAL OPHTHALMOLOGIST
Diabetic retinopathy for GENERAL OPHTHALMOLOGIST
 
Avengers of DME -AJAY DUDANI MUMBAI RETINA CENTRE
Avengers of DME -AJAY DUDANI MUMBAI RETINA CENTREAvengers of DME -AJAY DUDANI MUMBAI RETINA CENTRE
Avengers of DME -AJAY DUDANI MUMBAI RETINA CENTRE
 
Diabetes awarness presentation new
Diabetes awarness presentation newDiabetes awarness presentation new
Diabetes awarness presentation new
 
PSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptx
PSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptxPSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptx
PSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptx
 
46191.pptx
46191.pptx46191.pptx
46191.pptx
 
Matta rice
Matta riceMatta rice
Matta rice
 

Mais de Inaiara Bragante (20)

Aula Abordagem Comunitária
Aula Abordagem ComunitáriaAula Abordagem Comunitária
Aula Abordagem Comunitária
 
Edital prmfc2018
Edital prmfc2018Edital prmfc2018
Edital prmfc2018
 
Regimento2017
Regimento2017Regimento2017
Regimento2017
 
Rmnf2222
Rmnf2222Rmnf2222
Rmnf2222
 
Cmaj.140703.full
Cmaj.140703.fullCmaj.140703.full
Cmaj.140703.full
 
Pós teste
Pós testePós teste
Pós teste
 
Pré teste
Pré testePré teste
Pré teste
 
Pós teste
Pós testePós teste
Pós teste
 
Comunicando más notícias
Comunicando más notíciasComunicando más notícias
Comunicando más notícias
 
Ciclo de vida individual e familiar
Ciclo de vida individual e familiarCiclo de vida individual e familiar
Ciclo de vida individual e familiar
 
Bb dm – extra
Bb dm – extraBb dm – extra
Bb dm – extra
 
Bb dm2
Bb dm2Bb dm2
Bb dm2
 
Conduta terapeutica
Conduta terapeuticaConduta terapeutica
Conduta terapeutica
 
Caso clinico alcool
Caso clinico alcoolCaso clinico alcool
Caso clinico alcool
 
M1 d2a6q1 cage_2009-03-13
M1 d2a6q1 cage_2009-03-13M1 d2a6q1 cage_2009-03-13
M1 d2a6q1 cage_2009-03-13
 
Tratamento farmacológico em dependência química helio -sandra
Tratamento farmacológico em dependência química  helio -sandraTratamento farmacológico em dependência química  helio -sandra
Tratamento farmacológico em dependência química helio -sandra
 
Rz clin residentes_brasil_2
Rz clin residentes_brasil_2Rz clin residentes_brasil_2
Rz clin residentes_brasil_2
 
Aula31 07 2014
Aula31 07 2014Aula31 07 2014
Aula31 07 2014
 
Aula31 07 2014
Aula31 07 2014Aula31 07 2014
Aula31 07 2014
 
Casos clínicos (3)
Casos clínicos (3)Casos clínicos (3)
Casos clínicos (3)
 

Who mec for patients with endocrine disorders

  • 1. 7/20/2014 WHO MEC for patients with endocrine disorders http://www.uptodate.com.myaccess.library.utoronto.ca/contents/image?imageKey=OBGYN%2F69329&rank=1~150&search=contracep%C3%A7%C3%A3o&source=image_view&view=print&topicKey=OBGYN/5459&source=se… 1/2 Official reprint from UpToDate®  www.uptodate.com ©2014 UpToDate® World Health Organization medical eligibility for contraceptive use: Endocrine conditions Condition COC CIC P/R POP DMPA NET­EN LNG/ETG Implants Cu­IUD LNG­IUD Diabetes History of gestational disease 1 1 1 1 1 1 1 1 Non­vascular disease Non­insulin dependent 2 2 2 2 2 2 1 2 Insulin dependent 2 2 2 2 2 2 1 2 Nephropathy/retinopathy/neuropathy 3/4 3/4 3/4 2 3 2 1 2 Other vascular disease or diabetes of >20 years' duration 3/4 3/4 3/4 2 3 2 1 2 Thyroid disorders Simple goitre 1 1 1 1 1 1 1 1 Hyperthyroid 1 1 1 1 1 1 1 1 Hypothyroid 1 1 1 1 1 1 1 1 1: A condition for which there is no restriction for the use of the contraceptive method. 2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks. 3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method. 4: A condition which represents an unacceptable health risk if the contraceptive method is used. COC: low­dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen­only pill; DMPA: depot medroxyprogesterone acetate; NET­EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu­IUD: copper intrauterine device; LNG­IUD: levonorgestrel­releasing IUDs; E­IUD: copper­IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness­based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization. Reproduced with permission from: http://www.who.int/reproductive­health/publications/mec/summary.html. Copyright © 2006 World Health Organization.
  • 2. 7/20/2014 WHO MEC for patients with endocrine disorders http://www.uptodate.com.myaccess.library.utoronto.ca/contents/image?imageKey=OBGYN%2F69329&rank=1~150&search=contracep%C3%A7%C3%A3o&source=image_view&view=print&topicKey=OBGYN/5459&source=se… 2/2 Graphic 69329 Version 2.0